Territory Account Executive - Rare Disease Biotech KS MO NE

Alnylam; Kansas City (MO); On-site; USD 120,000 - 180,000; Full time

Job summary

Alnylam is seeking an experienced Business Account Executive (BAE) to commercially represent GIVLAARI and OXLUMO in the United States, covering Kansas, Missouri and Nebraska. You will drive physician and patient identification, build territory strategies, and collaborate with internal and external stakeholders to advance access and disease awareness.

Responsibilities include executing speaker programs, sponsorships, and educational activities across academic and clinical sites, while achieving

Qualifications

• Bachelor's degree required.
• 5+ years in biotech, specialty pharma, or medical devices.
• Experience in Rare Disease or related fields preferred.
• Willingness to travel overnight including travel to Boston and other sites.

Responsibilities

• Drive physician and patient identification through HCP-driven strategies and territory plans.
• Develop and execute territory strategy/account plans to launch and grow products.
• Collaborate with internal/external stakeholders to ensure access at site of care and proper logistics.
• Lead and participate in speaker programs, sponsorships, and exhibits across multiple sites.
• Routinely report territory dynamics, prescriber trends, and competitive activity to the Regional Business Director.

Skills

Territory planning

Cross-functional collaboration

Data analysis

Communication

Entrepreneurial mindset

Account management

Education

Bachelor's degree

Job description

Alnylam is seeking an experienced Business Account Executive (BAE) to commercially represent GIVLAARI and OXLUMO in the United States, covering Kansas, Missouri and Nebraska. You will drive physician and patient identification, build territory strategies, and collaborate with internal and external stakeholders to advance access and disease awareness.

Responsibilities include executing speaker programs, sponsorships, and educational activities across academic and clinical sites, while achieving